These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 31471287)

  • 1. Fedratinib Becomes New Option in Myelofibrosis.
    Cancer Discov; 2019 Oct; 9(10):1332. PubMed ID: 31471287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
    Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
    Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fedratinib in myelofibrosis.
    Mullally A; Hood J; Harrison C; Mesa R
    Blood Adv; 2020 Apr; 4(8):1792-1800. PubMed ID: 32343799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
    Mesa RA; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Abraham P; Lord-Bessen J; Tang D; Guo S; Ye X; Harrison CN
    Hemasphere; 2021 May; 5(5):e553. PubMed ID: 33969273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
    Schiffer M; Kowalski A; Zhao J; Bewersdorf JP; Lewis RS; Zeidan AM
    Drugs Today (Barc); 2020 Dec; 56(12):755-768. PubMed ID: 33332482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
    Liu JX; Chen W; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatment strategies for myeloproliferative neoplasms.
    Bose P; Masarova L; Verstovsek S
    Rinsho Ketsueki; 2019; 60(9):1176-1185. PubMed ID: 31597841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
    Assi R; Verstovsek S; Daver N
    Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections.
    Cowart K; Worley M; Rouby NE; Sando K
    Ann Pharmacother; 2019 Dec; 53(12):1192-1199. PubMed ID: 31319681
    [No Abstract]   [Full Text] [Related]  

  • 11. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
    Bose P; Verstovsek S
    Cancer; 2016 Mar; 122(5):681-92. PubMed ID: 26717494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The regulatory saga of fedratinib.
    Khal S; Prasad V; Palumbo A
    J Oncol Pharm Pract; 2021 Jul; 27(5):1248-1250. PubMed ID: 34013823
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 16. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
    Matlock A; Allan N; Wills B; Kang C; Leikin JB
    Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rose B
    Hosp Pharm; 2016 Jun; 51(6):491-2. PubMed ID: 27354752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights July-September 2016.
    Rubio T
    Hosp Pharm; 2016 Dec; 51(11):941-943. PubMed ID: 28057955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights October - December 2016.
    Rose BJ
    Hosp Pharm; 2017 Feb; 52(2):153-154. PubMed ID: 28321144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.